Vanda Pharmaceuticals Files 8-K: Regulation FD Disclosure
Ticker: VNDA · Form: 8-K · Filed: Jan 27, 2025 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | Jan 27, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulation-fd, disclosure, corporate-actions
Related Tickers: VNDA
TL;DR
Vanda Pharma dropped an 8-K on Jan 25th about Reg FD. Check it out.
AI Summary
Vanda Pharmaceuticals Inc. filed an 8-K on January 27, 2025, reporting an event that occurred on January 25, 2025. The filing indicates a Regulation FD Disclosure and includes information related to common stock and a Series A Junior Participating Preferred Stock Purchase Right. The company is incorporated in Delaware and its principal executive offices are located in Washington, DC.
Why It Matters
This filing provides important disclosures under Regulation FD, which ensures that material information is broadly disseminated to the public, impacting investor understanding and market fairness.
Risk Assessment
Risk Level: low — The filing is a standard current report (8-K) for a Regulation FD disclosure, which is routine and does not inherently indicate significant new risks.
Key Numbers
- 001-34186 — SEC File Number (Identifies Vanda Pharmaceuticals Inc. in SEC filings.)
- 03-0491827 — IRS Employer Identification No. (Tax identification number for Vanda Pharmaceuticals Inc.)
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- January 27, 2025 (date) — Filing Date
- January 25, 2025 (date) — Earliest Event Reported Date
- Regulation FD (regulation) — Disclosure Type
- Delaware (jurisdiction) — State of Incorporation
- Washington, DC (location) — Principal Executive Offices
FAQ
What specific information was disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure but does not detail the specific information within the provided text. Further review of the full document is required.
What is the significance of the Series A Junior Participating Preferred Stock Purchase Right?
The filing mentions a Series A Junior Participating Preferred Stock Purchase Right in relation to common stock, suggesting a potential shareholder rights plan, but the specific details and implications are not elaborated in this excerpt.
When did the event triggering this 8-K filing occur?
The earliest event reported in this 8-K filing occurred on January 25, 2025.
What is Vanda Pharmaceuticals Inc.'s primary business sector?
Vanda Pharmaceuticals Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
Where are Vanda Pharmaceuticals Inc.'s principal executive offices located?
Vanda Pharmaceuticals Inc.'s principal executive offices are located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037.
Filing Stats: 610 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-01-27 08:22:15
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Ma
Filing Documents
- d869105d8k.htm (8-K) — 25KB
- 0001193125-25-012740.txt ( ) — 181KB
- vnda-20250125.xsd (EX-101.SCH) — 4KB
- vnda-20250125_def.xml (EX-101.DEF) — 13KB
- vnda-20250125_lab.xml (EX-101.LAB) — 22KB
- vnda-20250125_pre.xml (EX-101.PRE) — 14KB
- d869105d8k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 27, 2025 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary